Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in post-COVID-19 syndrome (PCS) - PoCoVIT
Key facts
- Where
- Berlin, NémetországSee the site
- Phase
- 2. fázis
Where in Németország
- Charite Universitaetsmedizin Berlin KöRBerlin, NémetországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Charite Universitaetsmedizin Berlin KöR
- Trial code
- EU 2023-504826-21-00
- Record updated
- 2024. november 13.
- Original description
Improvement in memory satisfaction from baseline to week 8 when comparing methyl-prednisolone with placebo in PCS patientsRead full original descriptionShow less
Improvement in memory satisfaction from baseline to week 8 when comparing methyl-prednisolone with placebo in PCS patients
Inclusion: History of confirmed (PCR or serology or rapid antigen detection and sick note or comparable certificate after Dec 21, 2023) SARS-CoV-2 infection according to WHO criteria; Ongoing symptoms of PCS for ≥ 3 months; Self-reported cognitive deficits at screening.
Exclusion: Previous medical history of gastric ulcer, osteoporosis and/or previous vertebral fractures, rheumatological disease or metabolic disease including diabetes mellitus; Ongoing immunosuppressive therapy; Any ongoing central nervous system disease; Any major psychiatric disease within the last 10 years; Patient is pregnant or breastfeeding at screening.